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Abstract 
The market for new psychoactive substances has increased markedly in recent years and there is now 
a steady stream of compounds appearing every year. Benzodiazepines consist of only a fraction of the 
total number of these compounds but their use and misuse has rapidly increased. Some of these 
benzodiazepines have only been patented, some of them have not been previously synthesised and the 
majority have never undergone clinical trials or tests. Despite their structural and chemical similarity, 
large differences exist between the benzodiazepines in their pharmacokinetic parameters and 
metabolic pathways and so they are not easily comparable. As benzodiazepines have been clinically 
used since the 1960s many analytical methods exist to quantify them in a variety of biological 
matrices and it is expected that these methods would also be suitable for the detection of 
benzodiazepines that are new psychoactive substances. Illicitly obtained benzodiazepines have been 
found to contain a wide range of compounds such as opiates which presents a problem since the use 
of them in conjunction with each other can lead to respiratory depression and death. The aim of this 
review is to collate the available information on these benzodiazepines and to provide a starting point 
for the further investigation of their pharmacokinetics which is clearly required. 
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The use and misuse of benzodiazepines 
The use and misuse of new psychoactive substances (or “legal highs”) has increased 
significantly around the world in the past 10 years [1] and has to date showed no signs of 
slowing. In Europe alone the total number of new compounds reported by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has risen rapidly since 2007 
with 101 new psychoactive substances reported to the EMCDDA in 2014 [2] and 98 in 2015 
[3]. The majority of these compounds have been synthetic cannabinoids, cathinones and 
phenylethylamines [2]. One group of these compounds, the benzodiazepines, have received 
limited attention but their use has increased significantly in the past few years. The abuse 
potential for benzodiazepines was recognised early in their use and led to 33 benzodiazepines 
being placed under control by the UN Convention on Psychotropic Substances 1971 [4]. 
Benzodiazepines are one of the most prescribed groups of drugs around the world with the 
limited available data suggesting that 5.6% of Americans filled a benzodiazepine prescription 
in 2013 [5]. In England over 5 million doses of diazepam alone were dispensed in 2014, 
whilst the total number of prescriptions issued for benzodiazepines stood at more than 10.4 
million, indicating their widespread use [6] Benzodiazepines are also linked to a significant 
number of deaths, both via abuse as a drug in their own right and also as part of a deliberate 
poly pharmacy regime [7]. They are commonly implicated in cases of opioid overdoses, 
where benzodiazepines are detected in 50 – 80 % of heroin-related deaths and in 40 – 80 % of 
methadone-related deaths in various countries around the world [7]. Benzodiazepines also 
account for around 28 – 45 % of drug induced deaths in Europe [2]. A study of 1500 people in 
2014 used an internet-based survey to investigate the reasons for the abuse of 
benzodiazepines and Z-drugs in the United Kingdom (Z-drugs such as zopiclone and 
zolpidem are structurally different from benzodiazepines but also act via the -aminobuytric 
acid type-A (GABAA) receptor). The study found that the majority of abuse of Z-drugs and 
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benzodiazepines occurred because users were trying to alleviate stress, to help with sleep or 
to get high [8]. Unfortunately the study did not differentiate between benzodiazepines or Z-
drugs but as a result of their similar effects it is likely that they are used interchangeably. 
When used in combination with other drugs (such as opioids/opiates) the aim of 
benzodiazepine use is typically to enhance and/or prolong the high or to reduce the 
withdrawal effects of the other drugs [9]. 
Outside normal prescription methods, benzodiazepines are obtained via various routes such 
as diversion of prescriptions, the illicit market and internet purchasing which is thought to be 
a rising trend [10]. In 2016 the Research and Development (RAND) corporation published a 
report suggesting that the UK had the second largest number of online vendors of illegal 
drugs on the darknet (with the US first) but that UK vendors averaged the most transactions 
per month [11].  
In recent years an increasing number of new psychoactive substances (NPS) benzodiazepines 
have appeared for sale in various countries. NPS are defined by the United Nations Office on 
Drugs and Crime as “substances of abuse, either in a pure form or a preparation, that are not 
controlled by the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on 
Psychotropic Substances, but which may pose a public health threat.”[12]. These new 
psychoactive substances are often sold online and labelled for use as ‘research chemicals’ 
only, even though they are implicitly intended for human consumption. Many of these NPS-
benzodiazepines have never undergone the clinical testing that is required of licenced 
medicines and the increasing availability of them may therefore pose serious health risks to 
poly drug users and benzodiazepine-dependent patients who can no longer obtain their 
prescription and may turn to other means of obtaining benzodiazepines. We introduce the 
general way that benzodiazepines are commonly classified (duration of action, half-life and 
chemical structure) the mechanism of action of benzodiazepines and review what is known to 
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date about these NPS-benzodiazepines including user experiences, their pharmacology, 
pharmacokinetics and analytical detection.  This data is summarised in Error! Reference 
source not found. and was obtained from a variety of published journal articles except the 
user experiences which were obtained from chat and comments on internet forums such as 
Reddit [13], Bluelight [14], Flashback [15] and UK Chemical Research [16]. Caution should 
be taken when interpreting these user experiences as any experiences are subjective and users 
may have ingested other compounds at the same time. Instead they serve as a rough guide as 
to the likely effects that may be expected. 
The rise of the NPS-benzodiazepines 
The first illicit benzodiazepines identified in Europe to the EMCDDA were phenazepam 
(fenazepam) and nimetazepam in 2007 [17]. Phenazepam is a prescription drug in the former 
Soviet bloc [18] and  in the intervening years it was detected in an increasing number of cases 
around the world [19-25]. This led to it being scheduled in the UK and other countries [26-
28]. Recently, phenazepam was placed in schedule VI of the 1971 UN Drug control 
convention [29]. The benzodiazepine-derivative etizolam was the next compound to be 
detected to the EMCDDA in 2011[30]. It belongs to a class of compounds known as 
thienodiazepines and is commonly prescribed in Japan [31]. The naming of benzodiazepines 
and their derivatives is discussed in the next section of this review – “Classification of 
benzodiazepines”. Its appearance mirrored that of phenazepam; a prescription drug in a 
country outside the UK which subsequently found its way to the UK market. Pyrazolam was 
the next benzodiazepine to appear on the market and was notable as this was the first 
benzodiazepine to appear that was not a prescription drug in any country [32]. Following this, 
multiple benzodiazepines were detected to the EMCDDA that have not been licenced for 
clinical use anywhere in the world.  These benzodiazepines include flubromazepam and 
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diclazepam in 2013 [33] along with meclonazepam, nifoxipam and deschloroetizolam (a 
thienodiazepine) in 2014 [34]. Clonazolam and flubromazolam are also thought to have first 
appeared in 2014 [10] and were subsequently reported to the EMCDDA. Various other 
benzodiazepines such as adinazolam, nitrazolam and metizolam (another thienodiazepine) 
have all been reported to the EMCDDA in the 2015 implementation report [35]. Two other 
benzodiazepines, 3-hydroxyphenazepam (a metabolite of phenazepam [18]) and flutazolam (a 
Japanese prescription drug [36]) have been detected separately in tablets seized in Sweden in 
2015 by the Medical Products Agency (MPA), with the use and spread of flutazolam being 
monitored and 3-hydroxyphenazepam being subject to an investigation by the MPA [37]. 
Flunitrazolam, desmethylflunitrazepam (also known as fonazepam) and cloniprazepam were 
also detected by the MPA in 2016 [38]. Bromazolam [39], desalkylflurazepam  (also known 
as fludiazepam or norflurazepam) [39] and 4-chlorodiazepam (also known as Ro5-4864) [40] 
are also thought to have appeared at various points in 2016. The years that these 
benzodiazepines appeared and their year of patient (if available) has been summarised in 
Table 2 and the timeline can be viewed in Figure 1. Currently hundreds of benzodiazepines 
have been patented and described in the scientific literature and these are not expected to be 
the last benzodiazepines that are detected in the so called “explosion” of new psychoactive 
substances.  
NPS-benzodiazepines and thienodiazepines have been implicated in nine drug-related deaths 
in England and Wales between 2013 – 2014  as either being the cause of death or having 
contributed to death [41]. In 2016, the Psychoactive Substances Act was introduced in the 
UK [42] with the aim of stopping the “cat and mouse” game of a NPS being produced to 
circumvent legislation, being controlled and then another being produced. This legislation 
restricts the production, sale and supply of drugs that are “psychoactive”.  It is expected 
following the introduction of this Act that a fall in supply and use of NPS-benzodiazepines 
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may be expected. However, phenazepam and etizolam are now both controlled 
benzodiazepines in the UK under the Misuse of Drugs Act (1971) [43]  but are still regularly 
identified in post mortem cases and in drug-impaired drivers in the UK [21, 22].  
Classification of benzodiazepines 
Benzodiazepines have traditionally been classified in one of three ways, either by;  
1) Their duration of action. Benzodiazepines that have durations of action under 24 hours are 
short-acting while those with durations of action above 24 hours are long-acting [44].  
2) Their elimination half-life (t½). Typically, this is consists of four classifications; ultra-
short (t½, <6 h), short (t½, 6 h), intermediate (t½ 6-24 h) and long (t½ > 24 h). The reason for 
these four classifications is because the duration of action of the benzodiazepines can be 
extended by active metabolites [45-47]. 
3) Their chemical structure. The core structure of benzodiazepines is a diazepine ring fused to 
a benzene ring. A phenyl ring is usually attached to the diazepine ring (Figure 2). Most 
common benzodiazepines are 1,4-benzodiazepines (Figure 2A) (e.g. diazepam [46]) but 1,5-
benzodiazepines (Figure 2B) (e.g. clobazam [48]) also exist. A whole host of derivatives of 
this basic benzodiazepine structure are possible. Some of them involve the addition of 
another cyclic system to the molecule, for example a triazole ring (Figure 2C) (e.g. 
alprazolam [49]), imidazole ring (Figure 2D) (e.g. midazolam [50])  or oxazole ring (Figure 
2E) (e.g. cloxazolam [51]). Others involve replacement of the benzene ring with a thiophene 
or pyridine ring. One such group of benzodiazepine derivatives are the thienodiazepines (e.g. 
etizolam [52]) (Figure 2F). They differ in structure by the replacement of a benzene ring with 
a thiophene ring but they have similar anticonvulsant, anxiolytic and sedative properties [52-
54]. Thienotriazolodiazepines (Figure 2G) (e.g. brotizolam [54]) have a triazole ring fused to 
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the diazepine ring, much like the triazolobenzodiazepines. 2,3-benzodiazepines such as 
tofisopam exist [55] (Figure 2H) but despite them having the benzodiazepine ring structure 
they exhibit different pharmacological properties compared with the other benzodiazepines; 
they act via the 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) 
glutamate receptor but still exhibit anxiolytic activity [56, 57]. To the best of the authors’ 
knowledge there are no reports of abuse of 2,3-benzodiazepines.  It may only be possible to 
classify the NPS-benzodiazepines by structure until more information becomes available. 
Despite being structurally different, thienodiazepines will be grouped together with 
benzodiazepines as “NPS-benzodiazepines” in this review. 
Mechanism of action of benzodiazepines 
The main sites of action of benzodiazepines in the human body are gamma-Aminobutyric 
acid A (GABAA) receptors. GABAA receptors are ligand-gated ion channels which are 
endogenously activated by gamma-Aminobutyric acid (GABA), the major inhibitor 
neurotransmitter in the central nervous system (CNS) [58]. Their structure consists of five 
protein subunits that surround a central pore through which Cl
-
 ions can permeate [58]. 
Binding of GABA to the receptor triggers the chloride ion pore to open leading to an 
inhibition of neural signals.  There are seven receptor subunit families (α 1-6, β 1-3 γ 1-3, δ, 
ε, π, θ) but the most common GABAA receptor combination is α2β2γ, which comprises 
around 43 % of all GABAA receptors in the CNS, with 10 other combinations also identified 
[59, 60]. These isoforms are preferentially distributed within specific regions of the CNS 
[61]. As a result, the receptors have different pharmacological properties and this helps to 
explain the differing pharmacological effects observed with the benzodiazepines. The role of 
GABAA receptor subunits and addiction has been reviewed by Tan and colleagues[62], with 
the α1 subunit containing GABAA receptors thought to be those that are involved in the 
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addictive properties of benzodiazepines [62-64]. Benzodiazepines bind between the α1 and 
γ2 subunits at a site that is distinct from the GABA binding site. They act as positive 
allosteric modulators, increasing the affinity of GABA to the receptor and potentiating the 
response of the receptor to GABA [65]. Ethanol also binds to the GABAA receptor [66] as do 
another class of drugs, the barbiturates [67]. An exception to the benzodiazepines binding to 
the GABAA receptor can be found for 4-chlorodiazepam (Ro5-4864) which recently appeared 
as an NPS-benzodiazepine [40]. 4-chlorodiazepam binds exclusively to the translocator 
protein (18 kDa) (TSPO 18 kDa) [68], initially known as the peripheral benzodiazepine 
receptor [69]. TSPO (18 kDa) is found throughout the body and has a variety of biological 
functions which have been extensively reviewed [69-71] and it is thought to have 
considerable potential therapeutic value as a pharmacological target [72, 73]. Certain 
compounds that bind to TSPO (18 kDa) can exhibit typical benzodiazepine effects such as 
being anxiolytic without causing some side effects associated with benzodiazepine use such 
as sedation [74]. However 4-chlorodiazepam has been found to induce anxiety and cause 
convulsions in rats despite being a sedative [75, 76]. Other benzodiazepines such as diazepam 
also experience some binding to TSPO (18 kDa) [70, 77] but the majority of their 
pharmacological effects result from the binding of them to GABAA receptors [71].  
Benzodiazepine pharmacokinetics 
The pharmacokinetics of benzodiazepines vary widely. The most common route of 
administration for prescription benzodiazepines is orally but they are also given 
intramuscularly, intravenously or rectally [44]. When administered orally there is a wide 
variation between the time taken to reach tmax [44]. For example the NPS-benzodiazepine 
phenazepam reaches a tmax between 2 – 4 hours following a 2 mg dose [78] while 
flubromazepam is only thought to reach tmax after 11.8 hours following a 4 mg dose [79]. The 
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time of day that benzodiazepines are administered can affect tmax; triazolam exhibits a tmax of 
~13 minutes when taken in the morning compared with ~22 minutes when taken in the 
evening and the half-life (t½) was similarly affected (2.94 hours in the morning versus 3.77 
hours in the evening) [80]. It was thought that this is as a result of the longer fasting period 
prior to the dose [80]. 
Benzodiazepines can have vastly differing half-lives and this has been well reviewed [44]. An 
important point of note is that the half-life of active benzodiazepine metabolites can be far 
greater than that of the parent benzodiazepine. For example, desmethyldiazepam (marketed 
as nordazepam) is an active metabolite of several benzodiazepines and can have a half-life of 
96 ±34 hours following oral administration of prazepam [45] or 120 hours following 
diazepam [46]. Similarly, desalkylflurazepam is the active metabolite of flurazepam and can 
have a half-life of 40 – 144 hours following oral administration [47]. Desalkylflurazepam is 
now known to be sold as a novel psychoactive substance [39]. The main monohydroxylated 
metabolite of the NPS-benzodiazepine flubromazepam can be detected in urine up to 28 days 
following ingestion compared to 6 days and 20 hours for the parent compound indicating a 
higher half-life for the metabolite [79].  Similarly, diclazepam is found only in very low 
concentrations in serum and urine for just over four days. However its metabolites are 
detectable for longer time periods; delorazepam is detectable for 6 days in urine and 10 days 
in serum, lorazepam is detectable for 19 days in both serum and urine and lormetazepam is 
detectable for 11 days in urine [81]. 
As well as the variations discussed for maximum plasma concentrations and half-lives, other 
pharmacokinetic parameters exhibit large differences for the benzodiazepines. For example 
triazolam has a bioavailability of 44 % [82] versus a bioavailability of  97 % for diazepam 
[83], diazepam is 97 % bound to plasma proteins [84] while alprazolam is only 70 % bound 
to plasma proteins [85]. Volumes of distribution also differ; oxazepam and the NPS-
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benzodiazepine flubromazepam have relatively low volumes of distribution (0.27 l kg
-1
 [86] 
and 0.73 l kg
-1
 [79] respectively) versus a high volume of distribution of 4.4 l kg
-1
 for 
flunitrazepam [87].  
The differences briefly mentioned above mean that the pharmacokinetics of benzodiazepines 
cannot be easily compared and specific knowledge of their individual pharmacokinetic 
parameters is required to understand how they behave in the body. Typical blood 
concentrations, half-lives and volumes of distribution (where known) for the NPS-
benzodiazepines is provided in Table 1. 
The majority of drug metabolism occurs in the liver, primarily by oxidative metabolism 
mediated by the cytochrome P450 (CYP450) family of enzymes [88].  CYP3A4 is the 
enzyme most commonly involved in the metabolism of benzodiazepines [89]. However other 
enzymes are also involved in the metabolism of benzodiazepines such as; CYP3A5, 
CYP2C19, CYP2B6, CYP2C18 and CYP2C9 [90]. The CYP3A4 enzyme can also conjugate 
benzodiazepines containing a nitro group with a glutathione group which can result in 
cytotoxicity in the liver [89]. Polymorphisms in metabolic enzymes can lead to an alteration 
in the metabolism of specific drugs.  There is only limited evidence that polymorphisms of 
CYP3A4/5 clinically affect benzodiazepine metabolism [91].  However CYP2C19 
polymorphisms have been shown to influence the metabolism of benzodiazepines to a 
significant degree particularly with clobazam [92], etizolam [93] and diazepam [94, 95]. In 
one study subjects who were CYP2C19 poor metabolisers exhibited an elimination half-life 
for diazepam which was twice that of normal metabolisers [96]. The effect of polymorphisms 
could not only lead to greater toxicity but also a longer detection window after 
administration. The phase II metabolic pathways of benzodiazepines have been less widely 
studied but are thought to involve uridine 5'-diphospho-glucuronosyltransferase (UGT) 
enzymes particularly UGT2B15 [97], UGT1A9 [98], UGT2B7 [98] and UGT1A4 [99]. 
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Polymorphisms in N-acetyltransferase 2 (NAT2) enzymes can affect the metabolism of 
benzodiazepines that undergo N-acetylation. This has been observed for a metabolite of 
clonazepam, 7-aminoclonazepam, where variant NAT2 polymorphisms caused a reduction in 
the rate of its metabolism [100].  
In order to detect benzodiazepine use it is important to be able to detect the parent drug as 
well as any metabolites. Depending on the type of benzodiazepine “class” and the additional 
chemical substituent groups on the core structure the benzodiazepines undergo similar phase I 
metabolism. The common metabolic pathways for 1,4-benzodiazepines and some 
triazolo/imidazobenzodiazepines are shown in Figures 3 and 4 respectively.  Oxidation is the 
primary phase I metabolic pathway observed for the majority of benzodiazepines. Typically, 
this involves hydroxylation on the same carbon atom on the diazepine ring, either labelled as 
position-3 (e.g. phenazepam [101]) or position 4 (e.g. clonazolam [10]). Hydroxylation at the 
α-position is also thought to occur for some benzodiazepines (e.g. flubromazolam [10]). N-
demethylation of the tertiary amine located on the diazepine ring of diclazepam has been 
described [81] whilst benzodiazepines containing a nitro group (e.g. meclonazepam [10]) 
undergo reduction. For phase II metabolism, benzodiazepines that contain hydroxyl groups 
typically undergo phase II glucuronide conjugation (e.g. lorazepam and oxazepam [102]) 
without any phase I metabolism. Benzodiazepines containing a 3-hydroxy group typically 
have a shorter duration of action as they are directly metabolised to glucuronidated forms that 
are inactive [103]. Some benzodiazepines can be detected as benzophenones (they are either 
directly metabolised to these compounds or experience some form of physical degradation) in 
urine after administration of the parent drug (e.g. alprazolam [104], nitrazepam [105], and 
phenazepam [106]). The structures of the NPS-benzodiazepines are provided in Figures 2A-H 
and Tables 2 – 5 and their metabolic routes are provided in Figures 3, 4 and Table 8.   
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Once benzodiazepines are metabolised they are mainly eliminated in urine with between <1 
% to ~20 % of the parent drug excreted unchanged with glucuronide being the most common 
metabolite [44]. As benzodiazepines follow common patterns it should be possible to predict 
the likely metabolites and routes of elimination of the NPS-benzodiazepines.  
In order to detect the use of NPS-benzodiazepines, give appropriate clinical treatment people 
who have been exposed to the NPS-benzodiazepines and to interpret their blood/plasma 
concentrations it is important to have pharmacokinetic, analytical and clinical data.  With this 
in mind we have collated the current available data on the NPS-benzodiazepines within this 
review.  
Analytical Detection of NPS-benzodiazepines 
It is important in toxicological analysis that analytical methodology is able to detect, identify 
and quantify drugs in a large number of matrices. As benzodiazepines are routinely used in 
clinical practice throughout the world, a large number of methods exist for their detection and 
quantification. The analytical methodologies for the determination of benzodiazepines in 
biological samples (blood, plasma, vitreous, oral fluid, hair, nails and others) have been 
recently reviewed [107, 108]. It is also important to understand whether analytical 
methodologies are likely to detect previously unknown benzodiazepines. The common 
methodological sequence during systematic toxicological analysis is detection, identification 
and then finally quantitation [109].  Toxicology laboratories commonly utilise immunoassays 
for presumptive detection before confirmation with other analytical techniques as a result of 
the large numbers of samples they may acquire. The advantage of the use of an immunoassay 
for screening is the lack of absolute selectivity of immunoassay antibodies that target the 
general structure of drug (such as benzodiazepines) rather that the specific drug (such as 
diazepam or phenazepam) [110]. Two recent publications investigating the cross reactivity of 
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standard commercial immunoassay drug screening to new NPS benzodiazepines in both 
blood and urine have shown that new NPS benzodiazepines would be detected by current 
immunoassay screens [111, 112]. Potential misidentification could occur however for 
structural isomers such as diclazepam and 4-chlorodiazepam (Ro5-4864) [113]. It is likely 
that new, as yet unknown, benzodiazepines would be detected by current commercial 
benzodiazepine immunoassays. This hypothesis was backed up by data from the Swedish 
STRADA project (a project that monitors the occurrence and trends of new psychoactive 
substances) where 390 clinical samples tested positive in a benzodiazepine immunoassay 
screen and subsequently tested negative in a classical LC-MS/MS benzodiazepine screen. 
Later, 40% of these samples were confirmed as containing NPS-benzodiazepines [114]. 
Following the presumptive detection of benzodiazepines confirmation and quantitation are 
needed. Typically HPLC [115, 116] with or without a mass spectrometer is used but GC-MS 
[117, 118] and capillary electrophoresis [119] have been utilised. As the NPS-
benzodiazepines are extremely similar in structure to clinically used benzodiazepines it is 
expected that they would be able to be detected using similar methods. LC-TOF-MS 
currently gives the best methodology for the detection of any emerging NPS benzodiazepines 
as it is possible to search for compounds based on the molecular formula alone [120] 
although care needs to be taken with any isomers that may lead to misidentification. Sample 
preparation is an important step in the detection and quantitation of NPS benzodiazepines. 
The two common techniques used are that of liquid-liquid extraction (LLE) and solid phase 
extraction (SPE) [109]. SPE gives advantages amongst others of higher selectivity and 
increased extraction efficiency and recovery over LLE [121]. This could however be a 
disadvantage when trying to identify new compounds that have not previously been detected 
and may not elute from a specific SPE column.  
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One SPE technique that is becoming increasingly popular is the quick, easy, cheap, effective, 
rugged, safe (QuEChERS) dispersive SPE (dSPE) technique [122]. The use of a primary and 
secondary amine phase (PSA) allows easier removal of complex matrix components such as 
blood [123]. The QuEChERS technique has been shown to increase the recoveries of 
benzodiazepines extracted from various biological matrices such as blood and urine [124] and 
also from milk-based alcoholic drinks (where benzodiazepines are often added illicitly) 
which provides a complex matrix for extraction as a result of the high number of proteins and 
fatty acids [125].  
The methods that are currently available for the detection and quantitation of NPS 
benzodiazepines in body fluids are listed in Table 7. LC-MS has been used to detect both 
flubromazepam and its metabolites in urine and serum [79] and also pyrazolam [126]. 
Pyrazolam does not appear to produce metabolites according to one study [126] but is 
detectable in serum for up to 50 hours but it is excreted in urine for up to 6 days following 
ingestion of 1 mg which provides a fairly large window of detection for analysis [126]. 
Diclazepam is found only in very low concentrations for just over four days following 
ingestion of 1 mg [81]. However its metabolites are discernible for longer time periods with 
delorazepam detectable for 6 days in urine and 10 days in serum, lorazepam 19 days in both 
serum and urine and lormetazepam 11 days in urine [81]. Flubromazepam and its metabolites 
also exhibit a low level of detection in urine using immunoassays [79] [127] [112]. However, 
by the use of LC-MS, the monohydroxylated metabolite was detectable for 28 days following 
ingestion in the urine samples, compared with 23 days in the plasma samples providing an 
extremely long window of detection for the drug [79]. Other NPS-benzodiazepines would be 
expected to be similarly detectable.  
The metabolic pathways for benzodiazepines are fairly similar (see  Figures 3 and 4) and this 
allows metabolites to be predicted and actively searched for when analysing samples using 
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techniques such as LC-MS [128, 129]. As a result of the aforementioned similar metabolic 
pathways, care must be taken when interpreting the apparent presence of a metabolite. For 
example, diclazepam is metabolised to lorazepam, lormetazepam and delorazepam which are 
all prescription drugs [81]. Likewise 3-hydroxyphenazepam has been sold on its own as an 
NPS-benzodiazepine but is a metabolite from both phenazepam [18] and a Russian 
prescription benzodiazepine cinazepam [130]. Desalkylflurazepam is a metabolite of several 
drugs including flurazepam [131], midazolam [132] and the Japanese prescription drugs 
flutoprazepam [133] and fludiazepam [134]. 
NPS Benzodiazepine Stability 
With any detection, identification and quantification of a drug it is important to have 
information on the stability of the drug and any possible changes in the drug concentration 
that may happen during transportation and/or storage [135]. There have been numerous 
studies on the stability of benzodiazepines in matrices such as blood and urine at 
temperatures from 20 °C to -80 °C [136-139]. Nitrobenzodiazepines (such as flunitrazepam, 
clonazepam and nitrazepam) and chlordiazepoxide have been found to be the most unstable 
especially in bacterially-contaminated specimens [136, 140]. Two studies have been carried 
out investigating the stability of NPS benzodiazepines (pyrazolam, diclazepam, 
flubromazepam, meclonazepam, phenazepam, etizolam, nifoxipam, deschloroetizolam, 
clonazolam, flubromazolam and flutazolam) but only in urine for 1 month and 7 months [128, 
141]. These studies showed that flubromazepam, clonazolam, nifoxipam and meclonazepam 
(the latter three are nitrobenzodiazepines) were unstable in urine (at ambient temperature and 
at -4 °C). Meclonazepam was only detected at 8 % of its original concentration after 4 weeks 
at -4 °C and -20 °C after 4 weeks). Meclonazepam has also been shown to be unstable in 
plasma in glass, but not in polypropylene tubes at -20 °C [142]. These studies indicate that 
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any future nitrobenzodiazepines are likely to be unstable and suggest that all NPS 
benzodiazepines should be investigated for stability and that they should all be collected in 
tubes containing fluoride oxalate (1 %) and then stored at the lowest temperature possible 
(ideally -20 °C or lower) before analysis.    
Prediction of the pharmacological, toxicological and pharmacokinetic 
properties of benzodiazepines. 
The lack of both in vivo and in vitro pharmacological testing of the new psychoactive 
substances that are emerging can be overcome to an extent with the use of quantitative 
structure activity relationship (QSAR) modelling. This technique creates a model that relates 
biological activity to structural descriptors of the compound and is based on a learning set 
with known biological activity. Systematic in vivo and in vitro work has also been carried out 
in order to investigate the structural characteristics that relate to pharmacological activity.  
From these studies estimations of activity of novel 1,4–benzodiazepines (Figure 2A) can be 
estimated for half-life (t½), volume of distribution (Vd), bioavailability (F) [143] as well as 
the potential toxicity of benzodiazepines [144], showing that hydrazone fragments, primary 
amines and saturated heterocyclic ring systems lead to increases in toxicity  [144]. The 
biological activity of benzodiazepines was initially studied by Hester who determined the 
effects of substituents on the biological activity. This determined that 
triazolobenzodiazepines (Figure 2C) were more potent than the corresponding 1,4-
benzodiazepine [145, 146]. As for the 1,4–benzodiazepines, the R1, R3, R7 and R2’ positions 
(Figure 2A) are important for biological activity [147, 148].  The removal of the phenyl 
group removes the GABA potentiation by the compound but it can still bind to the GABA 
site [149]. QSAR studies identified the relative importance of each site to activity and also 
which functional groups could be added at various positions for optimal biological activity.  
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The R7 position was the most important position for increasing receptor affinity (30 % in the 
QSAR model) with the 10 optimal functional groups being CH2CF3 > I > Br > CF3 > Cl > 
C(CH3)3 > NO2 > F > N3 > CH=CH2 [150].  At the R1 position (37 % in the QSAR model) 
the most optimal groups were OH > F > NH2 > H > NHOH > C2H5 > Cl > CF3 > Br > CH3  
[156] and the tert-butyl substitution led to inactivity [157].  At the R2’ position (15 % in the 
QSAR model) the order of the most optimal groups was NO2 > F > CN > Cl > CF3 [150, 
151].  The influence that substitution at the R3 position has on biological activity is unclear 
and difficult to predict as a result of the formation of enantiomeric forms [152, 153] but it is 
thought to have limited influence on the biological activity [154]. In the literature there are 
measured binding affinities for desmethylflunitrazepam (fonazepam) and meclonazepam (log 
IC50) of 0.176 and 0.079 respectively with predicted values of 0.565 and 0.357 respectively 
[152, 153]. These results show that although QSAR can be useful for prediction it is not a 
replacement for traditional in vivo and in vitro testing. 
The composition of illicitly-sold NPS-benzodiazepines  
A major issue with the purchase of drugs online is that there is no guarantee of the quality of 
composition. Alprazolam is one of the most widely-prescribed benzodiazepines in the world 
therefore it is not surprising that it is often illicitly sold. However, the wide variety of drugs 
that are sold and stated to contain alprazolam is both remarkable and concerning. Mimic 
alprazolam tablets have been found to contain melatonin [155] or the opioid fentanyl [156]. 
EcstasyData.org is an independent testing laboratory, created primarily to reduce the potential 
harm of illicit ecstasy by providing data on the composition of ecstasy tablets [157]. 
However, a variety of other drugs are often sent in and tested. This independent testing 
laboratory utilises GC-MS, thin layer chromatography (TLC) and colour tests for analysing 
and identifying the materials that are supplied to them [157]. Other drugs that have been 
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found in alprazolam tablets include other clinically-used benzodiazepines, synthetic 
cannabinoids, synthetic opiates, Z-drugs, piperazines, barbiturates and clinically-used 
anaesthetics and antihistamines. Clonazepam tablets have been identified as containing the 
NPS-benzodiazepine clonazolam [157]. Etizolam tablets have been found to contain 
alprazolam, flubromazepam (an NPS-benzodiazepine) and also diphenylprolinol, a compound 
used as a designer drug [157]. Diclazepam tablets have been identified as containing 
nimetazepam [157], a widely-prescribed and abused drug in southeast Asia [158] and an 
NPS-benzodiazepine in Europe itself [17] and some illicit tablets of nimetazepam (also 
known as Ermin 5) have been found to contain phenazepam [159]. In addition, in the 2016 
EMCDDA drug report it was noted that alprazolam tablets had been identified as containing 
flubromazolam and diazepam tablets had been identified to contain phenazepam [3]. This is a 
huge problem for drug users as they may be inadvertently taking a drug potentially many 
times more harmful than expected as a result of the lack of information regarding drug-drug 
interactions. As mentioned previously, it is well known that the concurrent use of opioids, 
opiates and benzodiazepines can increase the risk of death [7, 160].  There have been 
sporadic reports of the use of benzodiazepines as either diluents or adulterants in heroin 
however this does not appear to be as common [161]. The majority of the data from 
EcstasyData.org is from the United States but samples are sent in from across the world with 
many appearing to have been purchased online in China [157]. With the increase of NPS-
benzodiazepines in recent years, this may become even more problematic.  
Summary 
The use and abuse of benzodiazepines is already common throughout the world. In recent 
years there has been a large increase in new psychoactive substances. Benzodiazepines are 
only a small subsection of the total number of new psychoactive substances but that number 
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is steadily increasing. NPS-benzodiazepines are appearing in a variety of countries across the 
world. NPS-thienodiazepines are appearing at a much slower rate, perhaps as a result of a 
lower usage clinically and the already widespread availability of benzodiazepines.  NPS-
benzodiazepines have been implicated in deaths in England and Wales and the increasing 
availability of all novel psychoactive substances led to the introduction of the Psychoactive 
Substances Act within the UK in 2016. It remains to be seen whether this will affect the 
supply and use of NPS-benzodiazepines because phenazepam and etizolam were placed 
under control in the UK under the Misuse of Drugs Act 1971 but are still regularly identified 
in post-mortem cases and in drug-impaired drivers within the UK. The same may be expected 
for the NPS-benzodiazepines. The pharmacokinetics and metabolic pathways of NPS-
benzodiazepines are not currently well understood and there can be huge variation in 
pharmacokinetic parameters between individual compounds. Further investigation is clearly 
needed to establish the exact pharmacology of these new psychoactive substances.
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Table 1: Pharmacological Details of NPS Benzodiazepines 
Drug Formula mW (g mol-1) 
Typical 
Recreational 
dose (mg) 
“Therapeutic”/DUID 
range in blood (mg l-
1 ) 
T1/2 (h) Vd (l kg-1) User reports of effects Refs 
3-hydroxyphenazepam C15H10BrClN2O2 365.6 0.5 – 2 - - - 
Anxiolytic, slight muscle relaxant, 
strongly sedating 
[14, 162] 
4-chlorodiazepam 
C16H12Cl2N2O 
319.2 - - - - No reports - 
Adinazolam 
 
C19H18ClN5 351.8 20 0.1 – 0.46 1 – 3 2.2 No reports [163-167] 
Bromazolam 
C17H13BrN4 353.2 1 - - - No reports - 
Clonazolam 
C17H12ClN5O2 353.1 0.5 - 1 0.0019 – 0.011 - - Slight euphoria, strongly sedating [168, 169] 
Cloniprazepam 
C19H16ClN3O3 369.8 2.5 - - - 
Slight anxiolytic, higher doses (>5-
10 mg) required for muscle 
relaxation, sedation in most users 
[170] 
Desalkylflurazepam 
C15H10ClFN2O 
288.7 5 - - - 
Strongly sedating and long lasting 
effects 
[16] 
Deschloroetizolam 
 
C17H16N4S 308.4 4 - 6 - - - 
Effects lasting 12 – 24 hours, 
anxiolytic, sedative effect, slight 
euphoria 
[14] 
Desmethylflunitrazepam 
(fonazepam) 
C15H10FN3O3 299.3 0.6 - - - Anxiolytic, muscle relaxant, sedation 
[171, 172] 
 
Diclazepam C16H12Cl2N2O 319.2 1 - 2 
0.0021 – 0.057 
 
 
42 - 
Effects lasting 5 – 12 hours, 
anxiolytic, useful for ‘tapering’ 
dependence of other 
benzodiazepines, low cognitive 
impairment, low recreational value. 
[81, 169] 
[162] 
 
Etizolam 
C17H15ClN4S 342.1 0.25 – 3 0.019 - 0.17 3.4 – 7.1 0.91 
Anxiolytic, euphoric, muscle 
relaxant, used as a sleep-aid 
[169] 
Flubromazepam C15H10BrFN2O 333.1 4 0.0047 – 1.2 106.4 - 
Effects lasting 18 – 24 hours, 
anxiolytic, mild euphoria, blackouts, 
sedating and muscle relaxant effects, 
[169] 
[88, 177]  
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short-term memory loss 
 
Flubromazolam C17H12BrFN4 371.2 0.15 – 0.25 0.0048 -0.10 - - 
Effects lasting 12 – 18 hours, 
anxiolytic, high tolerance to lower 
doses quickly observed, blackouts 
and memory loss, strongly sedating, 
higher doses of 2.5 – 4 mg have 
effects reported to last up to 3 days 
and strong memory loss and 
cognitive impairment. Ingestion of 3 
mg of flubromazolam 19 hours prior 
to hospitalisation has been reported 
in a patient. Severe respiratory 
failure, hypotension, central nervous 
system depression and brain damage 
were observed. 
[79, 169, 
173] 
 
Flunitrazolam C17H12FN5O2 337.3 0.1 - - - 
Strong sedative, slight amnesia 
reported, anxiolytic 
[168] 
Flutazolam 
C19H18ClFN2O3 376.8 4 - 12 0.014 ~3.3 690 L 
Strong anxiolytic, hypnotic, short 
acting (3 – 4 hours) 
[174, 175] 
Meclonazepam 
 
C16H12ClN3O3 329.7 2 - 3 0.01 – 0.1 80 100 L 
Low sedation, anxiolytic, muscle 
relaxant 
[10, 175, 
176] 
Metizolam 
(desmethyletizolam) 
C16H13ClN4S 328.8 2 0.000011 - - 
Anxiolytic and muscle relaxant, 
effects not as strong as etizolam 
[168, 177] 
Nifoxipam 
 
C15H10FN3O4 315.3 0.5 - 2 - - - 
Effects lasting 12 – 18 hours, 
anxiolytic , moderately sedating, 
mild euphoric, High doses can cause 
users to feel sleep-deprived, muscle 
relaxant 
[175, 178] 
Nimetazepam C16H13N3O3 295.3 5 0.0000134 12 - 21 - No reports 
[179-181] 
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Nitrazolam C17H13N5O2 319.3 0.5 – 2 - - - 
Anxiolytic, hypnotic, strongly 
sedating 
[182] 
Phenazepam C15H10BrClN2O 349.6 0.5 – 1 0.030 – 0.070 6 – 80 4.7 – 6.0 
Anxiolytic, extremely sedating, 
short-term memory loss often leads 
to users redosing, blackouts at higher 
doses, psychotic episodes, insomnia 
[101, 118, 
168, 183] 
Pyrazolam C16H12BrN5 354.2 1 0.074 17 - 
Effects lasting 6 – 7 hours, 
anxiolytic, low sedation, low 
hypnotic effect, low recreational 
value 
[126] 
[168, 169] 
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Figure 1: Timeline of the reporting of NPS-benzodiazepines to the EMCDDA 
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Table 2: Benzodiazepine patent years and EMCDDA report years 
Compound Year patented Year reported to the EMCDDA 
3-hydroxyphenazepam Not reported 2016 [46] [37] 
4-chlorodiazepam (Ro5-4864) 1964 [191] 2016 [40] 
Adinazolam 1976[192] 2015 [35] 
Bromazolam 1976 [193] 2016 [39] 
Clonazolam 1971 [194] 2014 [35] 
Cloniprazepam Not reported 2015 [184] 
Desalkylflurazepam Not reported 2016  [39] 
Deschloroetizolam 1998 [196] 2014 [34] 
Desmethylflunitrazepam 
(fonazepam) 
1963 [197] 2016 [38] 
Diclazepam 1964 [198] 2013 [33] 
Etizolam 1978 [199] 2011 [30] 
Flubromazepam 1962 [200] 2013 [33] 
Flubromazolam 1978 [201] 2014 [34] 
Flunitrazolam Not reported 2016 [38] 
Flutazolam 1970 [202] 2015 [37] 
Meclonazepam 1975 [203] 2014 [34] 
Metizolam 1988 [204] 2015 [35] 
Nifoxipam 1985 [205] 2014 [34] 
Nimetazepam 1963 [206] 2007 [17] 
Nitrazolam 1971 [194] 2015 [35] 
Phenazepam 1974 [207] 2007 [17] 
Pyrazolam 1979 [208] 2012 [32] 
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Figure 2A-D: Structure of benzodiazepines and derivatives 
A) 1, 4 - Benzodiazepine 
 
B) 1,5 – Benzodiazepine 
 
C) Triazolobenzodiazepine
 
D) Imidazobenzodiazepine 
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Figure 2E-H: Structure of benzodiazepines and derivatives 
A) Oxazolobenzodiazepine 
 
B) Thienodiazepine 
 
C) Thienotriazolodiazepine 
 
D) 2,3 – Benzodiazepine  
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Table 3: 1,4-benzodiazepine based NPS structures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 From Figure 2A 
Compound R1 R2’ R3 R7  
3-hydroxyphenazepam H Cl OH Br  
4-chlorodiazepam (Ro5-
4864) 
CH3 H H Cl Note:  4-chlorophenyl ring 
instead of phenyl ring at 
position 6 
Cloniprazepam Methylcyclopropane Cl H NO2  
Desalkylflurazepam H F H Cl  
Desmethylflunitrazepam 
(fonazepam) 
H F H NO2  
Diclazepam CH3 Cl H NO2  
Flubromazepam H F H Br  
Meclonazepam H Cl CH3 NO2  
Nifoxipam H F OH NO2  
Nimetazepam H H OH NO2  
Phenazepam H Cl H Br  
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 Table 4: Triazolobenzodiazepine based NPS structures 
   
 From Figure 2C 
Compound R1 R2’ R8  
Adinazolam CH2N(CH3)2 H Cl  
Bromazolam CH3 H Br  
Clonazolam CH3 Cl NO2  
Flubromazolam CH3 F Br  
Flunitrazolam CH3 F NO2  
Nitrazolam CH3 H NO2  
Pyrazolam 
 
CH3 None Br Note: pyridine ring instead of 
phenyl ring at position 6 
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 Table 5: Thienotriazolodiazepine based NPS structures 
 
 
 
 
 
 
 
 
 
 
 
 From Figure 2G 
Compound R2 R2’ R9 
Deschloroetizolam CH2CH3 H CH3 
Etizolam CH2CH3 Cl CH3 
Metizolam CH2CH3 Cl H 
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Table 6: Oxazolobenzodiazepine based NPS structures 
 From Figure 2E 
Compound R2’ R7 R10 
Flutazolam F CH2CH2OH Cl 
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Figure 3: General metabolic pathways for 1,4-benzodiazepines
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Figure 4: General metabolic pathways for triazolobenzodiazepines (also applies to 
imidazobenzodiazepines) 
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Table 7: Analytical methods for the analysis of NPS-benzodiazepines in biological matrices 
Analyte Matrix Analytical Method Internal Standard Extraction 
Limit of 
detection 
(ng ml-1) 
Linear range 
(ng ml-1) 
Limit of quantitation 
(ng ml-1) 
Ref. 
Adinazolam Plasma HPLC-UV Alprazolam LLE (ethyl acetate) ~5 10 – 800 10 [185] 
3-hydroxyphenazpem 
Phenazepam 
Blood 
Urine 
Vitreous 
Muscle 
Brain 
Liver 
 
LC-MS/MS Diazepam-d5 
LLE 
(hexane:ethylacetate 
7:3) 
0.3 
7 
16 - 100 
0.7 - 200 
0.7 
16 
[162] 
Clonazolam 
Meclonazepam 
Nifoxipam 
Urine LC-MS 
Methamphetamine-d5 
Pethidine-d4 
LLE Not provided Not provided Not provided [186] 
Clonazolam, 
Diclazepam 
Etizolam 
Flubormazepam 
Flubromazolam 
Pyrazolam 
Blood UPLC-MS/MS Diazepam-d5 
LLE 
(ethyl 
acetate:heptane 4:1) 
Same as LOQ Not provided 
1.4 
1.6 
1.4 
3.3 
0.37 
3.5 
[169] 
Pyrazolam 
Dicalzepam 
Flubormazepam 
Meclonazepam 
Phenazepam 
Etizolam 
Nifoxipam 
Deschloroetizolam 
Clonazolam 
Flubromazolam 
Flutazolam 
Urine LC-MS/MS 
Temazepam-d5 
Estazolam-d5 
Β-glucuronidation 
followed by dilute 
and shoot 
4 
2 
2.5 
1 
5 
2 
10 
2 
5 
2 
5 
10 – 1000 
2 – 200 
2.5 – 250 
1 – 100 
5 – 500 
5 – 500 
10 – 1000 
5 – 500 
5 – 500 
5 – 500 
5 – 500 
10 
2 
2.5 
1 
5 
5 
10 
5 
5 
5 
5 
[128] 
Desmethylflunitrazepam 
(fonazepam) 
Numerous methods reviewed by Katselou [178] 
Diclazepam Plasma/urine LC-MS 
Diazepam-d5 
Lorazepam-d4 
Nordazepam-d5 
Temazepam-d5 
Β-glucuronidation 
then LLE using 1-
chlorobutane and 
borate buffer (pH 9) 
0.25 0.25 – 100 Not provided [81] 
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Etizolam Plasma/Urine HPLC Alprazolam LLE 1 1-100 Not provided [187] 
Etizolam Plasma HPLC N/A N/A 0.3 Not provided 0.6 ng/ml [93] 
Etizolam Plasma/Urine GC-MS/MS Fludiazepam SPE Not provided 5-50 Not provided [188] 
Flubromazepam Plasma/Urine LC-MS/MS Nordazepam 
LLE (1-
chlorobutane) 
1 1-100 Not provided [79] 
Meclonazepam Plasma GC None LLE (butyl acetate) 0.1 0.6 – 20 0.6 [142] 
Meclonazepam Urine LC-MS-QTOF None Β-glucuronidation Not provided Not provided Not provided [186] 
Metizolam Urine LC-MS/MS 
Methyl-clonazepam & 
-OH-
ethylthoephyllin 
LLE 
(dichloromethane/n-
heptane/isopropanol 
(25/65/20) 
0.025 0.05 – 50 0.05 [177] 
Nifoxipam Numerous methods reviewed by Katselou [178] 
Nimetazepam Urine LC-MS/MS Nitrazepam-d5 SPE 0.05 0.05 – 100 0.1 [189] 
Phenazepam Plasma GC 
7-bromo-5-(2-
bromophenyl)-1,3-
dihydro-1,4-
benzodiazepin-2-one 
LLE (diethyl ether) 1-2 1-150 Not provided [190] 
Phenazepam Plasma GC-MS Prazepam SPE Not provided Not provided 1 [118] 
Phenazepam Plasma/Plasma LC-MS/MS Diazepam SPE 1.44 5 - 1000 3.06 [24] 
Phenazepam Plasma Dual-column GC Norclobazam LLE (ethyl acetate) 5 ng g-1 10 – 500 ng g-1 10 ng g-1 [191] 
Phenazepam Plasma LC-MS/MS Diazepam LLE (acetone) 12 100 – 1600 28 [25] 
Pyrazolam Plasma/Urine LC-MS/MS Alprazolam 
LLE (1-
chlorobutane) 
1 1-100 Not provided [126] 
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Table 8: Metabolic pathways and metabolites of NPS -benzodiazepines 
Compound Major Phase I metabolites (both in vivo and in vitro) Reference(s) 
3-hydroxyphenazepam None Known [184] 
4-chlorodiazepam (Ro5-4864) 
There appears to be a lack of information on the metabolic routes of this 
benzodiazepine but they are possibly similar to those observed for 
diclazepam such as N-demethylation and 3-hydroxylation 
No reference 
Adinazolam 
 
N-desmethyladinazolam 
N,N-didesmethyladinazolam 
α-hydroxyadinazolam, Estazolam 
[184] 
[192] 
Bromazolam 
No experimental studies to date but possible metabolites are 
hydroxylation at the α or 4 positions as is the case with other 
triazolobenzodiazepines 
No reference 
Clonazolam 
 
7-aminoclonazolam, 7-acetaminoclonazolam 
Hydroxyclonazolam 
[10, 193] 
Cloniprazepam 
Monohydroxylated cloniprazepam 
Clonazepam (dealkylation) 
Reduction of the 7-nitro to a 7-amino group 
7-aminoclonazepam (dealkylation and reduction) 
Hydroxylation and dealkylation 
Hydroxylation and dealkylation 
Oxidation of the 3-hydroxy group to a 3-keto group 
[184] 
Desalkylflurazepam 
It is unclear as to whether this would go further phase I metabolism or 
instead proceed directly to phase II metabolism as is the case when it is 
a metabolite from flurazepam 
[47] 
Deschloroetizolam 
 
Monohydroxylation (probable 9-methyl) 
Monohydroxylation (probable 2-ethyl) 
Monohydroxylation (probable position 6) 
Dihydroxylation (positions undetermined) 
[10, 176] 
Desmethylflunitrazepam 
(fonazepam) 
3-hydroxynorflunitrazepam 
Monohydroxylation (position undetermined) 
7-aminonorflunitrazepam 
[184] 
Diclazepam 
 
Delorazepam, Lorazepam 
Lormetazepam 
[81, 176] 
Etizolam 
 
Hydroxylation on the α-carbon of the 9-methyl group  
(also known as α-hydroxyetizolam) 
Hydroxylation on the α-carbon of the 2-ethyl group  
(also known as 8-hydroxyetizolam) 
[176, 187] 
Flubromazepam 
 
Monohydroxylation (possibly 3-hydroxy, undetermined) 
Debromination and monohydroxylation (possibly 3-hydroxy, 
undetermined) 
Monohydroxylation (either on the phenyl ring or the benzene ring, 
undetermined) 
[79, 176] 
Flubromazolam 
 
α-hydroxyflubromazepam 
4-hydroxyflubromazepam 
Dihydroxylation (α-hydroxy and 4-hydroxy) 
[10, 176] 
 
Flunitrazolam 
No experimental studies to date but possible metabolites are reduction of 
the 8-nitro group to a 8-amino group and hydroxylation at position 4 of 
the diazepine ring. 
No reference 
Flutazolam 
 
Oxazole ring-opening and elimination 
The above metabolite is thought to be the main metabolite present in 
plasma but other metabolic pathways do exist: 
N1-dealkylation (loss of CH2CH2OH), 3-hydroxylation 
Hydroxylation on either the fluorophenyl or chlorophenyl ring 
Both N1-dealkylation and 3-hydroxylation 
[36] 
Meclonazepam 
 
7-aminomeclonazepam, 7-acetaminomeclonazepam [176, 193] 
Metizolam 
2 mono-hydroxylated compounds 
Di-hydroxylated compound 
Hydroxylation (likely to be 2-ethyl or 6- position) 
[177, 184] 
Nifoxipam 
 
7-aminonifoxipam, 7-acetaminonifoxipam [176, 193] 
Nimetazepam Nitrazepam, 7-aminonimetazepam [189] 
Nitrazolam 8-aminonitrazolam [184] 
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Mono hydroxylated metabolite (likely either 4- or α- position) 
Phenazepam 
 
3-hydroxyphenazepam 
Hydroxylation and methoxy addition (positions undetermined) 
[18, 101] 
Pyrazolam 
 
No detectable metabolites in serum or urine [126] 
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This paper critically reviews both the stage of knowledge of the emerging NPS-benzodiazepines and 
also the analytical methods that can be used to detect them. 
